SUBSCRIBE
SUBSCRIBE

Phase III

Courtesy of Alexanderstock23/Shutterstock
Drug Development
AstraZeneca’s Tagrisso Improved Disease-Free Survival in NSCLC with EGFR Mutations by 89%
The company is presenting the study of Tagrisso during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.
May 29, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Business
Roche and Gilead Launch COVID-19 Trial to Test One-Two Punch of Actemra and Remdesivir
“As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi Garraway, Roche’s chief medical officer and head of Global Product Development.
May 28, 2020
 · 
3 min read
 · 
Mark Terry
jejim/Shutterstock
Drug Development
Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD
Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration.
May 27, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Efgartigimod showing positive results in the phase
Drug Development
Argenx’s Myasthenia Gravis Drug, Efgartigimod, Shows Positive Results in Late-Stage Trial
Argenx, based in Breda, the Netherlands, and Ghent, Belgium, announced positive topline results from its Phase III ADAPT clinical trial of efgartigimod for Myasthenia Gravis (MG).
May 26, 2020
 · 
3 min read
 · 
Mark Terry
BioForest
Clinical Catch-Up: May 18-22
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
May 22, 2020
 · 
9 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
 · 
17 min read
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
 · 
7 min read
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Press Releases
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
January 21, 2026
 · 
7 min read
Press Releases
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026
 · 
5 min read
Press Releases
Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
January 21, 2026
 · 
5 min read
Press Releases
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026
 · 
5 min read
Press Releases
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
 · 
7 min read
Press Releases
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
13 min read
Press Releases
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 19, 2026
 · 
13 min read
Press Releases
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
9 min read
Press Releases
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
January 19, 2026
 · 
17 min read
Press Releases
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 16, 2026
 · 
6 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
 · 
7 min read
Press Releases
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
January 15, 2026
 · 
34 min read
Press Releases
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant®
January 15, 2026
 · 
5 min read
Press Releases
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 14, 2026
 · 
13 min read
Press Releases
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 14, 2026
 · 
9 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Load More